secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0000950170-24-080021
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen appoints Afsaneh Mohebbi, Ph.D. as SVP Portfolio & Program Mgmt and Dave Borah, CFA as SVP IR & Corp Comms
--------------------------------------------------------------------------------

- Afsaneh Mohebbi, Ph.D. appointed SVP, Portfolio & Program Management; previously consultant to PepGen since Jan 2024.
- Dave Borah, CFA named SVP, Investor Relations & Corporate Communications; most recently SVP at Mural Oncology.
- Appointments effective immediately; CEO cites expertise as key ahead of clinical milestones in H2 2024.
- Mohebbi led Fabry drug Replagal and Firazyr approvals at Shire; Borah increased analyst coverage at Bicycle Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024080021/0000950170-24-080021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024080021/pepg-20240702.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-080021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer